Drug Trial Radar · NCT05275374
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
221
Planned (sponsor's estimate)
Start
Dec 31, 2025
Primary completion
Dec 30, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.
Conditions
- Cancer
- BRAF V600 Mutation
- Melanoma
- Colorectal Cancer
- Thyroid Cancer
- Nonsmall Cell Lung Cancer
Interventions
XP-102Drug
XP-102 will be administered orally once or twice daily in a continuous regimen.
TrametinibDrug
Trametinib will be administered 2mg orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the safety of XP-102.Time frame: 28 days
- Evaluate the pharmacokinetics of XP-102.Time frame: 28 days
- Establish maximum tolerated dose of XP-102.Time frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.